• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of diagpathBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleDiagnostic PathologyJournal Front Page
Diagn Pathol. 2012; 7: 13.
Published online Feb 1, 2012. doi:  10.1186/1746-1596-7-13
PMCID: PMC3277478

Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine

Abstract

Two studies recently reported around 10% of EGFR activating mutations in triple negative breast cancers from Asian patients. However, we did not find any EGFR activating mutation in a series of 229 breast tumor samples from European patients. Like in lung cancer, the EGFR mutation profiles seem to be related to the ethnical origin of patients. This is an important point that should be considered when developing anti-EGFR therapies.

Keywords: Breast Cancer, EGFR, activating mutations, triple negative, geographic variations

Commentary

We have read with great interest the study on Epidermal Growth Factor Receptor (EGFR) mutations in breast carcinoma by Ning Lv et al published in Diagnostic Pathology [1]. Since in lung cancer the choice of anti-EGFR therapy is based on the presence of EGFR activating mutations, and due to the importance to the EGFR pathway in breast cancer, it is crucial to evaluate the presence of these mutations in the different subtypes of breast cancer. The authors reported that, in their series of 139 breast cancers, two (1.4%) tumors harbored activating EGFR mutations in exon 19 and 21 of this gene. One tumor was classified as estrogen receptor (ER) (1/105, 0.8%) positive and the other was a triple negative (TN) tumor (1/10, 10%). Similarly, in a recent study on 70 TN breast cancers, which were previously described to often present an EGFR addiction, Teng et al. found 8 (11.4%) activating EGFR mutations in exon 19 and 21 [2]. Both works reported findings that were obtained using tumor samples from Asian patients. We recently analyzed a series of 229 TN tumor samples from European patients with primary breast cancer and found that none had activating EGFR mutations [3]. In previous reports concerning smaller series of Caucasians patients, no EGFR activating mutation was found whatever the subtype of breast cancer studied [4-6]. Similarly, in a cohort of 58 Japanese patients, Toyama et al failed to find exon 19 and 21 EGFR mutations [7]. These results underline geographic differences in the presence of EGFR activating mutations as it was already described for non-small cell lung cancer [8]. This mutational event, which appears to be mostly limited to Chinese patients with TN breast cancer, could be related to ethnic or environmental factors. However, the question of the origin of the geographical variations in the occurrence of EGFR mutations in lung and breast cancers is unresolved.

Interestingly, a case of breast metastasis from a primary lung cancer that was confirmed by the detection of the same EGFR mutation has been recently reported [9]. This observation confirms that the presence of this mutation is not an obstacle to metastasization/tumor cell growth in the breast microenvironment. Inversely, we should not forget that some breast cancer characteristics, like ER expression and HER2 over-expression, have been also described in lung cancers [10,11]. Lung and breast cancer subtypes seem to share some biomarkers and thus could respond to the same therapies.

At the time of personalized medicine in oncology, more than ever, molecular patterns break the limits of classifying tumors according to their localization. Mutation profiles have to be analyzed in sub-groups of specific populations. This is a new and promising challenge for the design of clinical trials involving targeted therapies.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

PJL has been involved in drafting the manuscript. WJ has been involved in the critical revision of the manuscript intellectual content. All authors read and approved the final manuscript.

References

  • Lv N, Xie X, Ge Q, Lin S, Wang X, Kong Y, Shi H, Wei W. Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagn Pathol. 2011;6(1):118. doi: 10.1186/1746-1596-6-118. [PMC free article] [PubMed] [Cross Ref]
  • Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, Yip GW, Bay BH, Tan PH. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13(2):R35. doi: 10.1186/bcr2857. [PMC free article] [PubMed] [Cross Ref]
  • Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, Bibeau F, Romieu G, Lamy P-J. Lack of EGFR activating mutations in European patients with triple negative breast cancer could emphasize geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Research. 2011;13(6):R133. doi: 10.1186/bcr3079. [PMC free article] [PubMed] [Cross Ref]
  • Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;18(8):1027–1033. doi: 10.1038/modpathol.3800438. [PubMed] [Cross Ref]
  • Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res. 2005;7(6):R1028–1035. doi: 10.1186/bcr1341. [PMC free article] [PubMed] [Cross Ref]
  • Generali D, Leek R, Fox SB, Moore JW, Taylor C, Chambers P, Harris AL. EGFR mutations in exons 18-21 in sporadic breast cancer. Ann Oncol. 2007;18(1):203–205. [PubMed]
  • Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer. 2008;8:309. doi: 10.1186/1471-2407-8-309. [PMC free article] [PubMed] [Cross Ref]
  • Broet P, Dalmasso C, Tan EH, Alifano M, Zhang S, Wu J, Lee MH, Regnard JF, Lim D, Koong HN. et al. Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res. 2011;17(11):3542–3550. doi: 10.1158/1078-0432.CCR-10-2185. [PubMed] [Cross Ref]
  • Fukumoto K, Usami N, Okasaka T, Kawaguchi K, Okagawa T, Suzuki H, Yokoi K. Late breast metastasis from resected lung cancer diagnosed by epidermal growth factor receptor gene mutation. Lung Cancer. pp. 352–353. [PubMed]
  • Marquez-Garban DC, Mah V, Alavi M, Maresh EL, Chen HW, Bagryanova L, Horvath S, Chia D, Garon E, Goodglick L, Pietras RJ. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011;76(9):910–920. [PMC free article] [PubMed]
  • Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, Yin Y, Liu P, Shu Y. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol. 2010;5(12):1922–1932. doi: 10.1097/JTO.0b013e3181f26266. [PubMed] [Cross Ref]

Articles from Diagnostic Pathology are provided here courtesy of BioMed Central

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...